STO · SOBI.ST
Swedish Orphan Biovitrum AB
SEK 488.00+SEK 9.80 (+2.05%)
Swedish Orphan Biovitrum AB’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
Loading market information…
STO · NANEXA.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Nanexa AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 33.42% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Nanexa AB (publ)’s next earnings report is currently expected on Nov 5, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nanexa AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nanexa AB (publ) is a firm dedicated to developing advanced drug delivery solutions through nanotechnology. The company leverages its proprietary PharmaShell platform, a nanobased system that utilizes atomic layer deposition (ALD) technology for drug administration. Furthermore, Nanexa is progressing NEX-18, a PharmaShell-based candidate specifically designed to address severe conditions such as Myelodysplastic Syndrome and Acute Myeloid Leukemia. The company was established in 2007 and is headquartered in Uppsala, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:29 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 488.00+SEK 9.80 (+2.05%)
Swedish Orphan Biovitrum AB’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
SEK 273.40+SEK 1.50 (+0.55%)
Getinge AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.18% below the high.
SEK 341.60+SEK 2.80 (+0.83%)
Sectra AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.29% below the high.
SEK 279.50+SEK 2.00 (+0.72%)
Medicover AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.89% below the high.
SEK 670.00SEK 0.00 (0.0%)
Camurus AB’s quoted price sits in the upper half of its reported 52-week range, 5.63% below the high.
SEK 319.40-SEK 0.80 (-0.25%)
BioArctic AB’s quoted price sits in the upper half of its reported 52-week range, 12.35% below the high.
SEK 0.17+SEK 0.00 (+1.49%)
Nanologica AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 92.44% below the high.
SEK 0.04+SEK 0.00 (+0.5%)
Spago Nanomedical AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 80.95% below the high.
